{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:30:22Z","timestamp":1783035022896,"version":"3.54.6"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T00:00:00Z","timestamp":1718582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le SIDA et les H\u00e9patites virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp & Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004634","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Doravirine is the latest NNRTI to be approved for the treatment of HIV-1 and has a different resistance profile from first-generation NNRTIs. Our aim was to investigate the virological efficacy of antiretroviral treatment including doravirine in people living with HIV-1 (PLWHIV), the factors associated with virological failure (VF) and those associated with the emergence of reverse transcriptase (RT) mutations in the case of VF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective national survey of PLWHIV who were either naive or experienced on antiretroviral treatment including doravirine was conducted. VF was defined as two consecutive plasma viral loads (VLs) of \u226550\u2005copies\/mL or one VL of \u2265200\u2005copies\/mL. Genotypic resistance tests were interpreted using the Stanford (v9.4.1) and ANRS (v33) algorithms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 589 PLWHIV treated with a doravirine-containing regimen, 8.5% were naive and 91.5% had prior antiretroviral experience; 56.9% were infected with HIV-1 B subtype. Overall, 88.3% and 85.1% of participants were virologically controlled at Month (M)3 and M6 of doravirine treatment, respectively. In multivariable analysis, CRF02_AG subtype, higher zenith plasma HIV-1 RNA VL, doravirine initiation in the context of failure and baseline V179D mutation presence were associated with VF. Among 88 PLWHIV who experienced virological failure at M6, 15.9% had a median of 2 (IQR 1\u20133) HIV RT mutations. In multivariable analysis, the only factor associated with the occurrence of mutations was a genotypic sensitivity score that was not fully sensitive.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study is one of the largest to characterize the virological efficacy of doravirine-containing regimens in clinical practice and to identify factors associated with VF or emergence of resistance mutations that should be considered in clinical management.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae194","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T10:16:23Z","timestamp":1718619383000},"page":"1974-1984","source":"Crossref","is-referenced-by-count":4,"title":["DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2032-4148","authenticated-orcid":false,"given":"Cathia","family":"Soulie","sequence":"first","affiliation":[{"name":"INSERM, Sorbonne Universit\u00e9, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix, laboratoire de virologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-698X","authenticated-orcid":false,"given":"Aliou","family":"Balde","sequence":"additional","affiliation":[{"name":"INSERM, Sorbonne Universit\u00e9, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djeneba","family":"Fofana","sequence":"additional","affiliation":[{"name":"INSERM, Sorbonne Universit\u00e9, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pital Universitaire Saint Antoine, laboratoire de virologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[{"name":"INSERM UMR 1137 IAME, Universit\u00e9 Paris Cit\u00e9, AP-HP Nord H\u00f4pital Bichat\u2013Claude-Bernard, laboratoire de virologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Bonnafous","sequence":"additional","affiliation":[{"name":"INSERM, Sorbonne Universit\u00e9, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix, laboratoire de virologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Sourice","sequence":"additional","affiliation":[{"name":"CHU Nantes, laboratoire de virologie , Nantes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"De Monte","sequence":"additional","affiliation":[{"name":"CHU Nice, laboratoire de virologie , Nice , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7022-2990","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Avettand-Fenoel","sequence":"additional","affiliation":[{"name":"INSERM, U1016; CNRS, UMR8104, Universit\u00e9 Paris Cite\u0301 , Paris , France"},{"name":"H\u00f4pital Necker, APHP GHU Centre\u2014Universit\u00e9 Paris Cit\u00e9, laboratoire de virologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Le Guillou-Guillemette","sequence":"additional","affiliation":[{"name":"CHU Angers, laboratoire de virologie, and Univ Angers, HIFIH, SFR ICAT , Angers , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bocket","sequence":"additional","affiliation":[{"name":"CHU Lille, Univ. Lille, laboratoire de virologie , Lille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3780-5844","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Raymond","sequence":"additional","affiliation":[{"name":"INSERM UMR 1291, CHU Toulouse Purpan, laboratoire de virologie , Toulouse , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Marque Juillet","sequence":"additional","affiliation":[{"name":"CH de Versailles, service biologie, unit\u00e9 de microbiologie , Versailles , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Anne","family":"Trabaud","sequence":"additional","affiliation":[{"name":"Hospices civils de Lyon, H\u00f4pital de la Croix Rousse, service de virologie, Institut des Agents Infectieux , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Montes","sequence":"additional","affiliation":[{"name":"CHU Montpellier, laboratoire de virologie, Univ Montpellier , Montpellier , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Maillard","sequence":"additional","affiliation":[{"name":"CHU de Rennes, laboratoire de virologie , Rennes , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Hartard","sequence":"additional","affiliation":[{"name":"CHRU Nancy, laboratoire de virologie , Nancy , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8906-3416","authenticated-orcid":false,"given":"Elodie","family":"Alessandri-Gradt","sequence":"additional","affiliation":[{"name":"CHU de Rouen, Universit\u00e9 de Rouen Normandie UNIRouen , Rouen , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Brochot","sequence":"additional","affiliation":[{"name":"Facult\u00e9 de pharmacie Amiens, CHU Amiens , Amiens , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Signori-Schmuck","sequence":"additional","affiliation":[{"name":"Service de virologie, Univ. Grenoble Alpes, CHU Grenoble Alpes , Grenoble , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert","family":"Assoumou","sequence":"additional","affiliation":[{"name":"INSERM, Sorbonne Universit\u00e9, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"additional","affiliation":[{"name":"INSERM, Sorbonne Universit\u00e9, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re\u2014Charles Foix, laboratoire de virologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,17]]},"reference":[{"key":"2024073123522995300_dkae194-B1","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123522995300_dkae194-B2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1128\/AAC.02403-13","article-title":"In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor","volume":"58","author":"Lai","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123522995300_dkae194-B3","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1128\/AAC.02650-15","article-title":"Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024073123522995300_dkae194-B4","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2024073123522995300_dkae194-B5","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"2024073123522995300_dkae194-B6","author":"European AIDS Clinical Society"},{"key":"2024073123522995300_dkae194-B7","author":"US Department of Health and Human Services (DHHS)"},{"key":"2024073123522995300_dkae194-B8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jmv.20522","article-title":"Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance","volume":"78","author":"Descamps","year":"2006","journal-title":"J Med Virol"},{"key":"2024073123522995300_dkae194-B9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"2024073123522995300_dkae194-B10","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"2024073123522995300_dkae194-B11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","article-title":"Switching to doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial","volume":"81","author":"Johnson","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024073123522995300_dkae194-B12","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1177\/09564624231195084","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: a real-life experience","volume":"34","author":"Calza","year":"2023","journal-title":"Int J STD AIDS"},{"key":"2024073123522995300_dkae194-B13","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/QAI.0000000000002730","article-title":"Real-life safety of doravirine in treatment-experienced, virologically suppressed PLWHIV","volume":"88","author":"Ciccullo","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024073123522995300_dkae194-B14","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1089\/aid.2022.0058","article-title":"Efficacy and safety of doravirine-based regimens in real life: a prospective monocentric French study","volume":"38","author":"Garcia","year":"2022","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2024073123522995300_dkae194-B15","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/QAI.0000000000003337","article-title":"Switching to doravirine in cART experienced patients: an effective and highly tolerated option with substantial cost savings","volume":"95","author":"Lanting","year":"2024","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024073123522995300_dkae194-B16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/jac\/dky464","article-title":"Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients","volume":"74","author":"Soulie","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024073123522995300_dkae194-B17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/QAI.0b013e3182237f74","article-title":"Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine","volume":"58","author":"Tambuyzer","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024073123522995300_dkae194-B18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dkt316","article-title":"Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing","volume":"69","author":"Melikian","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2024073123522995300_dkae194-B19","doi-asserted-by":"crossref","first-page":"e0164240","DOI":"10.1371\/journal.pone.0164240","article-title":"Switch to ritonavir-boosted versus unboosted atazanavir plus raltegravir dual-drug therapy leads to similar efficacy and safety outcomes in clinical practice","volume":"11","author":"Gantner","year":"2016","journal-title":"PLoS One"},{"key":"2024073123522995300_dkae194-B20","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1093\/jac\/dkw167","article-title":"Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients","volume":"71","author":"Bocket","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2024073123522995300_dkae194-B21","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/jac\/dkv099","article-title":"Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice","volume":"70","author":"Wirden","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2024073123522995300_dkae194-B22","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/jac\/dkz021","article-title":"Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients","volume":"74","author":"Marcelin","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024073123522995300_dkae194-B23","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1093\/jac\/dkab193","article-title":"Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey","volume":"76","author":"Marcelin","year":"2021","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1974\/58689051\/dkae194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/79\/8\/1974\/58689051\/dkae194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T06:13:17Z","timestamp":1722492797000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/79\/8\/1974\/7694252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,17]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,6,17]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae194","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,6,17]]}}}